Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | CES2 | O00748 | 2/20 | 0.60 |
| ▸ | CES1 | P23141 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL1680817 | 1.00 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL27946226 | 0.97 | LMNA (0.90) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL27946225 | 0.97 | LMNA (0.90) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL5313046 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL1050 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL255601 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL29777368 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL165161 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL21647917 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL9186573 | 0.95 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107162897-A | Method for preparing mandelic acid from styrene oxide | 南京工业大学 | 2017-09-15 | — | — | CN | claimed |
| CN-103450008-B | Method for recovering mandelic acid from waste water | JIANGSU BAOZONG & BAODA PHARMACHEM CO LTD | 2015-02-25 | — | — | CN | claimed |
| CN-115894886-B | Preparation method of polybutylene carbonate with improved crystallinity and molecular weight | 大连理工大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-115894886-A | Preparation method of polybutylene carbonate for improving crystallinity and molecular weight | 大连理工大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-107162897-A | Method for preparing mandelic acid from styrene oxide | 南京工业大学 | 2017-09-15 | — | — | CN | disclosed |
| EP-2488579-B1 | THERMOPLASTIC POLYMER COMPOSITION | MILLIKEN & CO (US) | 2017-05-03 | — | — | EP | disclosed |
| CN-102575059-B | Thermoplastic polymer composition | MILLIKEN & CO. (US) | 2014-10-01 | — | — | CN | disclosed |
| US-8779045-B2 | Thermoplastic polymer composition | MILLIKEN & COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| CN-102985509-A | Cooling liquid composition | SHISHIAI KK | 2013-03-20 | — | — | CN | disclosed |
| EP-2554621-A1 | COOLING LIQUID COMPOSITION | Shishiai-Kabushikigaisha (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-4239912-A | SALT FORMATION | AMERICAN CYANAMID COMPANY (US) | 1980-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | LMNA 1461/4885MAPK1 4717/4885CES2 2786/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | LMNA 1180/4885MAPK1 4671/4885CES2 3260/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | LMNA 1552/4885MAPK1 4783/4885CES2 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.